x

Posted 07 June, 2022

AILERON THERAPEUTICS INC appointed new CEO

CEO Change detected for ticker Nasdaq:ALRN in a 8-K filed on 07 June, 2022.


  On June 5, 2022, the Board of Directors of the Company appointed Manuel Aivado, M.D., Ph.D., the Company's President and Chief Executive Officer to serve as the Company's principal financial officer and principal accounting officer.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of AILERON THERAPEUTICS INC
Health Care/Life Sciences • Biotechnology
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Waltham, MA.
Market Cap
$25.8M
View Company Details
AILERON THERAPEUTICS INC by TradingView
Relevant filing section
Item 5.02 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


Aileron Therapeutics, Inc. (the "Company") previously announced on April 25, 2022 that Richard J. Wanstall, the Company's Chief Financial Officer, principal financial officer and principal accounting officer, notified the Company of his resignation, effective May 6, 2022. On June 5, 2022, the Board of Directors of the Company appointed Manuel Aivado, M.D., Ph.D., the Company's President and Chief Executive Officer to serve as the Company's principal financial officer and principal accounting officer. Dr. Aivado, age 52, has served as the President and Chief Executive Officer and as a member of the board of directors since September 2018. 

There is no arrangement or understanding between Dr. Aivado and any other person pursuant to which Dr. Aivado was selected as an officer. Dr. Aivado has no family relationships with any of the Company's directors or executive officers. There are no transactions and no proposed transactions between Dr. Aivado and the Company that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K